Su et al. revealed that the combination of NVP-AUY922 (a Hsp90 inhibitor) and BBR retards human colon adenocarcinoma cell proliferation by inhibiting cyclin dependent kinase 4 (CDK4) expression and inducing miRNA-296-mediated suppression of the Pin1-β–catenin–cyclin D1 signaling pathway. This evidence concerns the gene CDK4 and colon adenocarcinoma.